Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.
Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation ODD along with standard chemotherapy care for the treatment of pancreatic cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5299
Published Date: Oct 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the market growth are the increasing geriatric population around the world and the rising prevalence of obesity.
The market size of pancreatic cancer treatment is anticipated to attain a CAGR of 18% over the forecast period, i.e., 2023-2036.
Lack of skilled professionals and side effects of chemo and radiotherapy are estimated to be the growth hindering factors for the market expansion
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
The major players in the market are Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation.